Abstrakt

In the last decades, the tobacco industry has constructed a sophisticated system of deception and manipulation to market its profitable harmful products. From denying the link between smoking and lung cancer and promoting the allegedly “light” or “organic” cigarettes to systematically downplaying the dangers of passive smoking, the industry’s aim has consistently been to undermine scientific evidence and delay public health measures. Today, we are witnessing a new wave of downplaying risks, this time through modern, high-tech products such as e-cigarettes, heated tobacco products, nicotine pouches, and even nicotine toothpicks. Under the guise of “harm reduction” and the narrative of quitting combustible cigarettes (e.g., “Global Action to End Smoking”), the industry is repositioning itself, attempting to “pharmaceuticalize” its image – shifting away from deadly combustible cigarettes toward “less harmful alternatives”. While strategies may have evolved over time – ranging from crude denial to modern, tech-driven marketing – the ultimate goal has remained unchanged: maximizing profits by creating and maintaining a nicotine-addicted customer base.

Autoreninformation

Autoren

• M. Chaabouni¹
• M. Urlbauer²

Abteilungen

• ¹ Abteilung für Onkologie, Hämatologie, Palliativmedizin, Rheumatologie und Pneumologie, Asklepios Klinik Altona, Hamburg,
• ² Medizinische Klinik
• ³ , Klinikum Nürnberg Nord, Nürnberg

Adresse

Dr. (Univ. Sfax) Malek Chaabouni
Asklepios Klinik Altona
Paul-Ehrlich-Straße 1
22763 Hamburg
und
Dr. Matthias Urlbauer
Leiter der Tabakentwöhnung
Klinikum Nürnberg
Ernst Nathan Str. 1
90419 Nürnberg
Email: [email protected]; [email protected]

Log in for Subscribers

Citation